FDA Clears AutoGenomics' Thrombophilia Assay as IVD | GenomeWeb
NEW YORK (GenomeWeb News) — AutoGenomics today said its Infiniti Factor II and Factor V assays and automated instrumentation have received 510(k) clearance from the US Food and Drug Administration.
 
According to AutoGenomics, the assays may help diagnose the bleeding and clotting disorder thrombophilia.
 
The test is an in vitro diagnostic used on blood samples to detect DNA point mutations including Factor II Prothrombin G20210A and Factor V Leiden G1691A, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.